DE60229883D1 - Biologisch aktive peptide - Google Patents

Biologisch aktive peptide

Info

Publication number
DE60229883D1
DE60229883D1 DE60229883T DE60229883T DE60229883D1 DE 60229883 D1 DE60229883 D1 DE 60229883D1 DE 60229883 T DE60229883 T DE 60229883T DE 60229883 T DE60229883 T DE 60229883T DE 60229883 D1 DE60229883 D1 DE 60229883D1
Authority
DE
Germany
Prior art keywords
biologically active
active peptides
disclosed
nucleic acids
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229883T
Other languages
English (en)
Inventor
Wai Ming Wong
Kong Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CMS Peptides Patent Holding Co Ltd
Original Assignee
CMS Peptides Patent Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CMS Peptides Patent Holding Co Ltd filed Critical CMS Peptides Patent Holding Co Ltd
Application granted granted Critical
Publication of DE60229883D1 publication Critical patent/DE60229883D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60229883T 2001-07-13 2002-07-11 Biologisch aktive peptide Expired - Lifetime DE60229883D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90449201A 2001-07-13 2001-07-13
PCT/GB2002/003203 WO2003006492A2 (en) 2001-07-13 2002-07-11 Biologically active peptides

Publications (1)

Publication Number Publication Date
DE60229883D1 true DE60229883D1 (de) 2008-12-24

Family

ID=25419251

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60236330T Expired - Lifetime DE60236330D1 (de) 2001-07-13 2002-07-11 Biologisch aktive Peptide
DE60229883T Expired - Lifetime DE60229883D1 (de) 2001-07-13 2002-07-11 Biologisch aktive peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60236330T Expired - Lifetime DE60236330D1 (de) 2001-07-13 2002-07-11 Biologisch aktive Peptide

Country Status (24)

Country Link
EP (3) EP1790655B1 (de)
JP (3) JP4213581B2 (de)
KR (2) KR100889993B1 (de)
AT (2) ATE414099T1 (de)
AU (1) AU2002319423B2 (de)
BR (1) BR0210252A (de)
CA (2) CA2707767C (de)
DE (2) DE60236330D1 (de)
DK (2) DK1478659T3 (de)
ES (2) ES2316586T3 (de)
HK (2) HK1066552A1 (de)
IL (2) IL159827A0 (de)
MX (1) MXPA03011190A (de)
MY (1) MY138219A (de)
NO (2) NO332061B1 (de)
NZ (3) NZ553507A (de)
PL (2) PL211884B1 (de)
PT (2) PT1478659E (de)
RU (2) RU2425053C2 (de)
SA (1) SA04240478B1 (de)
SG (2) SG142165A1 (de)
UA (1) UA83989C2 (de)
WO (1) WO2003006492A2 (de)
ZA (2) ZA200401108B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210300C (zh) 2001-07-13 2005-07-13 一泰医药研究（深圳）有限公司 序列号29的生物活性肽
WO2004055042A1 (en) * 2002-12-18 2004-07-01 Pepharm R & D Limited Biologically active peptide conjugates
TWI322815B (en) * 2003-06-26 2010-04-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide comprising tyrosyl-seryl-valine (ysv)
TWI353252B (en) 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
CN1799623B (zh) * 2005-01-05 2011-01-26 康哲医药研究(深圳)有限公司 生物活性肽在制备用于防治关节炎的药物中的用途
EP2417981A1 (de) 2005-07-26 2012-02-15 CMS Peptides Patent Holding Company Limited Peptid PTTKTYFPHF und seine Verwendungen
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242821A (en) 1989-07-10 1993-09-07 Valio, Finnish Co-Operative Dairies' Association Lactococcus promoter and signal sequences for expression in bacteria
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
AU7142391A (en) * 1989-12-22 1991-07-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides as modulators of functional responses of intact cells
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
EP0707645B1 (de) 1993-06-15 2003-11-05 E.I. Du Pont De Nemours And Company Rekombinante spinnerseide analoge
JP3286420B2 (ja) 1993-09-28 2002-05-27 株式会社ユニシアジェックス 内燃機関の吸排気弁駆動制御装置
JPH10503643A (ja) 1994-06-17 1998-04-07 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 微生物中に遺伝物質を導入する方法およびその方法によってえられる形質転換体
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
AU719366B2 (en) 1995-10-24 2000-05-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel peptide
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
GB9710762D0 (en) * 1997-05-23 1997-07-23 Cancer Res Inst Royal Binding complexes
DE69732378D1 (de) 1997-05-27 2005-03-03 Hanil Synthetic Fiber Co Ltd Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
WO2000013025A1 (en) * 1998-08-31 2000-03-09 University Of Washington Stable isotope metabolic labeling for analysis of biopolymers
US6413530B1 (en) * 1999-04-21 2002-07-02 University Of Florida Research Foundation, Inc. Pesticidal peptides
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001032853A1 (en) * 1999-10-29 2001-05-10 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same

Also Published As

Publication number Publication date
RU2004104335A (ru) 2005-03-27
EP1790655A2 (de) 2007-05-30
PT1478659E (pt) 2009-01-02
CA2452417A1 (en) 2003-01-23
WO2003006492A2 (en) 2003-01-23
ATE466871T1 (de) 2010-05-15
MY138219A (en) 2009-05-29
DK1790655T3 (da) 2010-08-23
JP2004533846A (ja) 2004-11-11
KR100889993B1 (ko) 2009-03-25
SG185137A1 (en) 2012-11-29
NO20073914L (no) 2004-03-10
SA04240478B1 (ar) 2007-07-31
EP1790655B1 (de) 2010-05-05
NO332061B1 (no) 2012-06-11
CA2707767C (en) 2013-09-03
PL211884B1 (pl) 2012-07-31
ZA200509838B (en) 2007-11-28
PL368059A1 (en) 2005-03-21
RU2425053C2 (ru) 2011-07-27
EP1478659B1 (de) 2008-11-12
HK1066552A1 (en) 2005-03-24
IL159827A0 (en) 2004-06-20
DE60236330D1 (de) 2010-06-17
ES2345842T3 (es) 2010-10-04
CA2707767A1 (en) 2003-01-23
KR20040019058A (ko) 2004-03-04
DK1478659T3 (da) 2009-01-05
RU2305107C2 (ru) 2007-08-27
PT1790655E (pt) 2010-07-09
ATE414099T1 (de) 2008-11-15
WO2003006492A3 (en) 2003-12-31
SG142165A1 (en) 2008-05-28
PL208666B1 (pl) 2011-05-31
IL184227A (en) 2010-06-16
EP1478659A2 (de) 2004-11-24
IL184227A0 (en) 2007-10-31
KR100889992B1 (ko) 2009-03-25
EP1947109A2 (de) 2008-07-23
BR0210252A (pt) 2004-09-14
CA2452417C (en) 2013-08-20
RU2007108896A (ru) 2008-09-20
JP4316651B2 (ja) 2009-08-19
NZ553507A (en) 2008-07-31
EP1947109A3 (de) 2008-10-01
EP1790655A3 (de) 2007-10-10
NO20040134L (no) 2004-03-10
JP2007312785A (ja) 2007-12-06
JP2008263993A (ja) 2008-11-06
UA83989C2 (ru) 2008-09-10
HK1098767A1 (en) 2007-07-27
NZ529879A (en) 2007-12-21
MXPA03011190A (es) 2004-10-28
NZ544079A (en) 2007-10-26
ZA200401108B (en) 2006-05-31
KR20070070258A (ko) 2007-07-03
AU2002319423B2 (en) 2008-02-14
JP4213581B2 (ja) 2009-01-21
ES2316586T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
NO20073914L (no) Biologisk aktive peptider
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
DE60224508D1 (de) Wti-modifiziertes peptid
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE417618T1 (de) Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
BR0312889A (pt) Polipeptìdeo t20 peguilado
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DK1219299T3 (da) Allergivacciner og fremstilling deraf
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
TW200611913A (en) Biologically active peptides (Ⅲ)
FR2820425B1 (fr) Melange de peptides issus d'une proteine nef et leurs applications
BR0107799A (pt) Proteìna de interação de wt1 wtip
DE69707690T2 (de) Neue peptide und nootroper wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition